Lead Product(s) : Ziltivekimab
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk’s Ziltivekimab Hits Primary Endpoint in CKD Trial
Details : The RESCUE trial assessed the effect of once-monthly subcutaneous ziltivekimab on biomarkers of inflammation in patients with advanced CKD and elevated hsCRP.
Product Name : COR-001
Product Type : Antibody
Upfront Cash : Inapplicable
May 18, 2021
Lead Product(s) : Ziltivekimab
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable